Hasil Pencarian - Randy Sweis

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    295 Tumor cell- intrinsic expression of FGFR3 drives anti-PDL-1 immunotherapy resistance in a murine bladder cancer model

    295 Tumor cell- intrinsic expression of FGFR3 drives anti-PDL-1 immunotherapy resistance in a murine bladder cancer model oleh Thomas Gajewski, Randy Sweis, Erica Fleming-Trujillo, Jeffrey Bloodworth, Anthony Fernald, Aubrianna Ramsland

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    642 Decreased host PKC-delta is associated with the T cell-inflamed tumor microenvironment and improves anti-tumor immunity

    642 Decreased host PKC-delta is associated with the T cell-inflamed tumor microenvironment and improves anti-tumor immunity oleh Thomas Gajewski, Ayelet Sivan, Keston Aquino-Michaels, Jessica Fessler, Randy Sweis, Emily Higgs, Kyle Cron, Seoho Lee

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    58 Excluding treg epitopes and integrating CD8 and CD4 effector neoepitope content improves prognostic biomarker tool in bladder cancer

    58 Excluding treg epitopes and integrating CD8 and CD4 effector neoepitope content improves prognostic biomarker tool in bladder cancer oleh Michael Princiotta, Arjun Balar, Gary Steinberg, Randy Sweis, Guilhem Richard, Tzintzuni Garcia, Matthew Ardito, William Martin, Gad Berdugo, Anne de Groot

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors

    771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients wit... oleh Evan Hall, Adi Diab, Sajeve Thomas, Randy Sweis, Anthony El-Khoueiry, Naveen K Mehta, Jennifer S Michaelson, Laura Liu, Reham Abdel-Wahab, Jeffrey A Jones, Kaida Wu, Benjamin S Maciejewski

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

    756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects wi... oleh Bin Zhang, Marsha Crochiere, Anthony W Tolcher, Randy Sweis, Kartik Sehgal, Michael S Gordon, Shui He, Jason Henry, Alexander I Spira, Shiraj Sen, Sandip P Patel, Sondra Smyrnios, Dipali Unadkat

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study

    726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study oleh Minal Barve, Ahmad A Tarhini, Deepak Kilari, Randy Sweis, Timothy Yap, John Clark, Justin Gainor, Lu Gan, Ulka N Vaishampayan, Amna Sher, Yawen Ju, Susan Henry, Stephen DeWall, Asia McCune, Mo Qatanani

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

    666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients oleh Minal Barve, Ahmad A Tarhini, Deepak Kilari, Rana Mckay, Randy Sweis, Timothy Yap, Justin Gainor, Raghad Karim, Lu Gan, Lan Liu, David Park, Ulka N Vaishampayan, Amna Sher, Sunil Babu, Yawen Ju, Susan Henry

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: